BioCentury
ARTICLE | Clinical News

Vesneo latanoprostene bunod regulatory update

August 1, 2016 7:00 AM UTC

FDA issued a complete response letter to Valeant for Vesneo latanoprostene bunod to treat open-angle glaucoma or intraocular pressure. Valeant said FDA’s concerns arose following an inspection of a U.S. manufacturing facility and were not related to safety or efficacy. The company plans to meet with FDA to resolve the issue. ...